Katherine Beck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8507344/publications.pdf

Version: 2024-02-01

34 papers	2,231 citations	430754 18 h-index	526166 27 g-index
36 all docs	36 docs citations	36 times ranked	3248 citing authors

#	Article	IF	Citations
1	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 64-77.	3.7	506
2	Impaired Glucose Homeostasis in First-Episode Schizophrenia. JAMA Psychiatry, 2017, 74, 261.	6.0	328
3	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. Schizophrenia Bulletin, 2018, 44, 1301-1311.	2.3	187
4	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Molecular Psychiatry, 2019, 24, 549-561.	4.1	179
5	Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophrenia Bulletin, 2016, 42, 744-752.	2.3	174
6	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry,the, 2020, 7, 344-353.	3.7	147
7	Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. British Journal of Psychiatry, 2017, 211, 339-349.	1.7	118
8	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open, 2020, 3, e204693.	2.8	103
9	Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. Neuropsychopharmacology, 2017, 42, 941-950.	2.8	98
10	Antipsychotic plasma levels in the assessment of poor treatment response inÂschizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	2.2	76
11	Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology, 2016, 233, 1605-1621.	1.5	54
12	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	2.0	51
13	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatrica Scandinavica, 2014, 130, 427-438.	2.2	38
14	Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis. British Journal of Psychiatry, 2015, 206, 164-165.	1.7	25
15	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. Journal of Psychopharmacology, 2019, 33, 1248-1253.	2.0	24
16	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology, 2016, 233, 2425-2428.	1.5	22
17	Brain-relevant antibodies in first-episode psychosis: a matched caseâ€“control study. Psychological Medicine, 2018, 48, 1257-1263.	2.7	22
18	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology, 2019, 236, 3257-3270.	1.5	21

#	Article	IF	Citations
19	Perinatal interventions for mothers and fathers who are survivors of childhood sexual abuse. Child Abuse and Neglect, 2018, 80, 9-31.	1.3	16
20	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	2.4	14
21	Comment on â€œIn Vivo [¹⁸F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primatesâ€. ACS Chemical Neuroscience, 2019, 10, 768-772.	1.7	11
22	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	1.7	6
23	Optimising treatment of refractory schizophrenia. Psychopharmacology, 2013, 227, 373-374.	1.5	3
24	S19. EVIDENCE OF THE LIPID PARADOX IN PSYCHOSIS: A META-ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S330-S330.	2.3	2
25	Mind the mortality gap: the importance of metabolic function in mental illnesses. Psychopharmacology, 2013, 230, 1-2.	1.5	1
26	First-Episode Schizophrenia and Diabetes Riskâ€”Reply. JAMA Psychiatry, 2017, 74, 763.	6.0	1
27	Modelling Continuous Arterial Blood Data from MR-Compatible Sampler in Simultenous Pet-MRI Experiments. , 2019, , .		1
28	The Effects of Acute Î”9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 660-667.	1.1	1
29	Seclusion reviews. , 0, , 246-250.		1
30	Relationship Between Replay-Associated Ripples and Hippocampal N-Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia. Schizophrenia Bulletin Open, 2022, 3, .	0.9	1
31	42.1 BODY AND MIND: CARDIO-METABOLIC AND IMMUNE FUNCTION IN FIRST EPISODE PSYCHOSIS AND COMPARISON WITH CENTRAL NEUROFUNCTIONAL MEASURES. Schizophrenia Bulletin, 2018, 44, S68-S68.	2.3	0
32	Ward rounds. , 0, , 221-224.		0
33	Lithium toxicity. , 0, , 418-421.		0
34	Medical emergencies. , 0, , 401-404.		0